Content available at: https://www.ipinnovative.com/open-access-journals

IP International Journal of Orthopaedic Rheumatology

Journal homepage: https://www.ijor.org/

Editorial

Immunologic crosstalk in synovium cartilage and bone under inflammatory stress

Madhan Jeyaraman[1,2]*, Swaminathan Ramasubramanian[2], Naveen Jeyaraman[1,2]

[1]Dept. of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai, Tamil Nadu, India
[2]Dept. of Regenerative Medicine, Agathisha Institute of Stemcell and Regenerative Medicine (AISRM), Chennai, Tamil Nadu, India

Abstract

Inflammatory joint diseases involve a complex interplay among synovial membrane, articular cartilage, and subchondral bone. In rheumatoid arthritis, immune-mediated processes in synovium drive pannus formation that invades cartilage and bone, with fibroblast-like synoviocytes adopting aggressive phenotypes. In osteoarthritis, synovitis can precede gross cartilage degradation, with innate immunity and damage-associated ligands activating Toll-like receptors; this amplifies catabolic cytokines that disrupt cartilage homeostasis. Fibroblast-like synoviocytes govern matrix metalloproteinases and RANKL production for osteoclast differentiation, influencing bone remodeling. Synovial macrophages and T cells engage in reciprocal activation loops, promoting hyaluronan-dependent leukocyte adhesion and sustaining inflammation. Chondrocytes also contribute immunologically by secreting cytokines and presenting antigens to infiltrating immune cells. Bone cells, including osteoclasts and osteoblasts, further engage via RANK/RANKL and other factors to amplify joint destruction. Understanding this tri-tissue dialogue informs novel therapeutic avenues to interrupt destructive circuits and restore joint homeostasis.

Keywords: Synovial inflammation, Chondrocyte immunomodulation, Osteoimmunology, Fibroblast-like Synoviocytes (FLS), Cartilage-Bone Crosstalk, Rheumatoid and Osteoarthritis pathogenesis.

Received: 15-05-2025; **Accepted:** 02-06-2025; **Available Online**: 06-06-2025

1. Introduction

Several chronic joint disorders lack simple etiology. In rheumatoid arthritis, autoimmunity drives synovial inflammation that spreads to cartilage and bone.[1] Osteoarthritis once considered a cartilage-centric "wear and tear" syndrome now is recognized as involving low-grade synovitis and immune activation.[3] These paradigms highlight interactions among synovium, cartilage, and bone. Synovial inflammation often dictates symptom severity in osteoarthritis and predicts cartilage loss.[3] In rheumatoid arthritis, synovial fibroblasts and macrophages orchestrate an aggressive pannus that degrades matrix and primes osteoclasts.[1,2,4] Articular chondrocytes react to this milieu by shifting from homeostatic to proinflammatory phenotypes.[9] Subchondral bone responds via osteoimmune signaling that deepens joint damage.[10] This editorial explores current understanding of the immunologic dialogue across these tissues and suggests avenues to break destructive feedback loops.

2. Synovial Environment and Immune Activation

Synovial membrane comprises two layers: the intima, containing fibroblast-like synoviocytes (FLS) and macrophages, and the subintima, rich in blood vessels and stromal cells.[1,8] Under healthy conditions, resident macrophages maintain tolerance and limit immune activation, while FLS produce lubricants and support extracellular matrix.[8] In rheumatoid arthritis, genetic and epigenetic cues imprint FLS with an aggressive phenotype. These synoviocytes produce interleukins (IL-6, IL-8), chemokines, and matrix metalloproteinases (MMPs), perpetuating inflammation and matrix degradation.[2,4] Epigenetic modifications in RA FLS sustain proinflammatory gene expression even in periods of disease quiescence.[2] Furthermore, interactions between T cells and FLS occur via LFA-1/ICAM-1, leading to IL-1β production and further FLS activation independent of antigen specificity.[6]

Macrophage heterogeneity adds nuance. Homeostatic synovial macrophages form a barrier to prevent unnecessary

*Corresponding author: Madhan Jeyaraman
Email: madhanjeyaraman@gmail.com

http://doi.org/10.18231/j.ijor.2025.001

leukocyte influx. During inflammation, monocyte-derived macrophages infiltrate, shifting toward M1 proinflammatory phenotypes that release TNF-α and IL-1β.[8] These cytokines stimulate FLS to secrete RANKL, promoting osteoclastogenesis.[1,4] Crosstalk among synovial macrophages, FLS, and infiltrating lymphocytes sustains the inflammatory milieu. For instance, CD4 T cells co-cultured with FLS upregulate hyaluronan synthases and degrade hyaluronan, which then mediates monocyte adhesion, reinforcing synovitis.[7]

In osteoarthritis, synovitis arises from matrix fragments that activate Toll-like receptors on synovial fibroblasts and macrophages. Engagement of TLR2 and complement pathways by cartilage debris triggers cytokine release (IL-6, TNF-α, IL-1β).[3] Imaging studies confirm that synovitis correlates with pain severity and accelerated cartilage loss.[3] While not as aggressive as RA pannus, osteoarthritic synovitis nonetheless contributes to chondrocyte catabolism and subchondral bone remodeling.

3. Cartilage Immunology

Articular cartilage relies on chondrocytes to maintain matrix integrity via balanced anabolic and catabolic processes. In rheumatoid arthritis, synovial cytokines (TNF-α, IL-1β, IL-6) upregulate MMPs and ADAMTS in chondrocytes.[1] Chondrocytes can themselves produce IL-6 and MMPs under inflammatory conditions. They also upregulate toll-like receptors, sensing damage-associated molecular patterns (DAMPs) from degraded matrix, further fueling inflammation.[3,9] In osteoarthritis, chondrocytes adopt senescent or hypertrophic states. They express MHC II and secrete proinflammatory mediators (e.g., IL-6) that engage synovial cells.[9] Chondrocytes also present cartilage neoantigens to infiltrating T cells, promoting local adaptive responses.[9]

Recent narrative reviews highlight chondrocytes as active immunomodulatory cells rather than passive victims. They express cytokine receptors and TLRs, enabling them to sense and amplify low-grade inflammation.[9] Their cross-talk with synovial FLS occurs via soluble factors and exosomes, which can transport catabolic mediators and microRNAs to synovial cells.[9] This bidirectional flow complicates attempts to target a single cell type.

4. Bone Remodeling and Osteoimmune Signals

Subchondral bone and synovium share intimate anatomical proximity. In RA, synovial RANKL drives osteoclast differentiation, promoting bone erosion at cartilage interfaces.[1,4,10] FLS and macrophage subsets express RANKL and M-CSF, aiding osteoclast precursor recruitment.[4,8] In osteoarthritis, subchondral bone thickens initially but later develops cysts and microfractures, partly through osteoclast activation by immune mediators.[3,10]

Osteoimmunology, the field studying bone-immune interplay, reveals that bone cells influence immune cell function. Osteoblasts secrete chemokines that modulate lymphocyte homing, while osteocytes produce sclerostin and RANKL to regulate local immune responses.[10] Conversely, activated T cells and B cells secrete IL-17 and TNF-α, enhancing osteoclastogenesis.[10] Cytokines such as IL-6 and TNF-α thereby couple immune activation to bone loss in RA and OA.[10]

5. Intertissue Crosstalk

Emerging data underscore a network of signals among synovium, cartilage, and bone. For example, synovial hyaluronan deposition induced by CD4 T cell-FLS interactions facilitates monocyte adhesion, which in turn produces MMPs that breach cartilage.[7] Conversely, cartilage breakdown products activate synovial TLRs, compounding synovitis.[3,9] Osteoclast activity releases TGF-β and bone morphogenetic proteins that can affect synovial and cartilage cells.[10] Synovial macrophages sense fibroblast-derived GAS6 and CSF1, while fibroblasts depend on HBEGF from macrophages to sustain survival.[8] This interdependency suggests that interrupting one axis may reestablish joint homeostasis.

Metabolic reprogramming of synovial cells further intensifies crosstalk. RA FLS and macrophages exhibit glycolytic shifts similar to tumor microenvironments, promoting secretion of lactate and reactive oxygen species that impair cartilage.[5] This “reverse Warburg” effect sustains chronic inflammation and hinders resolution. Targeting metabolic pathways in synovial cells could dampen both local joint damage and systemic inflammation.[5]

6. Conclusions and Recommendations

Synovium, cartilage, and bone form an interdependent immunologic complex. In RA, aggressive synovial pannus invades and destroys cartilage and bone via FLS, macrophage, and T cell cooperation.[1,2,4] In OA, low-grade synovitis drives cartilage catabolism and subchondral bone changes.[3,9] Chondrocytes actively contribute to immune activation, while bone cells reciprocate by modulating immune cell differentiation and survival.[9,10] Metabolic shifts in synovium amplify this dialogue.[5]

Interventions should focus on multimodal approaches targeting key nodes in this network. In RA, therapies that reset FLS epigenetic programming (e.g., BET inhibitors) may disrupt synovial aggression.[2] In OA, blocking TLR activation on synovial cells or neutralizing synovial IL-6 offers promise to retard cartilage loss.[3,9] Modulating hyaluronan dynamics may reduce leukocyte adhesion and synovitis.[7] In bone, inhibitors of RANKL or sclerostin can decouple immune activation from osteoclastogenesis.[10]

Future research must identify biomarkers that reflect intertissue activation, such as synovial fluid microRNAs or cartilage breakdown fragments, to guide individualized therapy. Single-cell sequencing of synovial macrophages and fibroblasts can reveal pathogenic subsets for targeted depletion.[8] Integrating metabolic profiling with transcriptomics could uncover novel regulators of chronic inflammation in joint resident cells.[5]

Ultimately, simultaneous targeting of synovium, cartilage, and bone holds the greatest potential to prevent irreversible joint damage. Interdisciplinary studies uniting immunologists, rheumatologists, and bioengineers are essential to design microphysiologic joint-on-chip models that recapitulate tri-tissue interactions for preclinical testing.[7,10]

7. Conflict of Interest

None.

References

1. Otero M, Goldring MB. Cells of the synovium in rheumatoid arthritis. *Arthritis Res Ther*. 2007;9(5):220.
2. Nygaard G, Firestein GS. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. *Nat Rev Rheumatol*. 2020;16(6):316–33.
3. Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone. 2012;51(2):249–57.
4. Chang SK, Gu Z, Brenner MB. Fibroblast-like synoviocytes in inflammatory arthritis pathology: the emerging role of cadherin-11. *Immunol Rev*. 2010;233(1):256-66.
5. Falconer J, Murphy AN, Young SP, Clark AR, Tiziani S, Guma M, et al. Review: Synovial cell metabolism and chronic inflammation in rheumatoid arthritis. *Arthritis Rheumatol*. 2018;70(7):984–99.
6. Tran CN, Lundy SK, Fox DA. Synovial biology and T cells in rheumatoid arthritis. *Pathophysiology*. 2005;12(3):183–9.
7. Kang I, Hundhausen C, Evanko SP, Malapati P, Workman G, Chan CK, et al. Crosstalk between CD4 T cells and synovial fibroblasts from human arthritic joints promotes hyaluronan-dependent leukocyte adhesion and inflammatory cytokine expression in vitro. *Matrix Biol Plus*. 2022;14:100110.
8. Knab K, Chambers D, Krönke G. Synovial macrophage and fibroblast heterogeneity in joint homeostasis and inflammation. *Front Med (Lausanne)*. 2022;9:862161.
9. Sengprasert P, Kamenkit O, Tanavalee A, Reantragoon R. The immunological facets of chondrocytes in osteoarthritis: a narrative review. *J Rheumatol*. 2023:jrheum.2023-0816.
10. Ponzetti M, Rucci N. Updates on osteoimmunology: what's new on the cross-talk between bone and immune system. *Front Endocrinol (Lausanne)*. 2019;10:236.

Cite this article: Jeyaraman M, Ramasubramanian S, Jeyaraman N. Immunologic crosstalk in synovium cartilage and bone under inflammatory stress. *IP Int J Orthop Rheumatol*. 2025;11(1):1-3.